Global Allergy Immunotherapies Market 2021-2025: Increasing Prevalence of Allergies, Recent Approvals and Strong Pipeline, and Growing Market Consolidation -

·3 min read

The "Global Allergy Immunotherapies Market 2021-2025" report has been added to's offering.

The allergy immunotherapies market is poised to grow by $713.56 mn during 2021-2025, progressing at a CAGR of almost 8% during the forecast period.

The market is driven by the increasing prevalence of allergies, recent approvals and strong pipeline, and growing market consolidation.

This study identifies the technological advances in allergy diagnostics as one of the prime reasons driving the allergy immunotherapies market growth during the next few years. Also, emerging drug development technologies and the growing popularity of slit will lead to sizable demand in the market.

The report on allergy immunotherapies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The allergy immunotherapies market analysis includes product segment and geographic landscape.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading allergy immunotherapies market vendors that include Aimmune Therapeutics Inc., ALK-Abello AS, Allergy Therapeutics PLC, ASIT biotech, DBV Technologies SA, HAL Allergy BV, Jubilant Life Sciences Ltd., LETI Pharma SLU, Merck KGaA, and Stallergenes Greer Ltd.

Also, the allergy immunotherapies market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem

  • Impact of COVID-19 on pharmaceuticals

  • Value chain analysis

Market Sizing

  • Market definition

  • Market segment analysis

  • Market size 2020

  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary

  • Bargaining power of buyers

  • Bargaining power of suppliers

  • Threat of new entrants

  • Threat of substitutes

  • Threat of rivalry

  • Market condition

Market Segmentation by Product

  • Market segments

  • Comparison by Product

  • SCIT - Market size and forecast 2020-2025

  • SLIT - Market size and forecast 2020-2025

  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation

  • Geographic comparison

  • Europe - Market size and forecast 2020-2025

  • North America - Market size and forecast 2020-2025

  • Asia - Market size and forecast 2020-2025

  • ROW - Market size and forecast 2020-2025

  • Key leading countries

  • Market opportunity by geography

  • Market drivers

  • Market challenges

  • Market trends

Vendor Landscape

  • Overview

  • Landscape disruption

Vendor Analysis

  • Vendors covered

  • Market positioning of vendors

  • Aimmune Therapeutics Inc.

  • ALK-Abello AS

  • Allergy Therapeutics PLC

  • ASIT biotech

  • DBV Technologies SA

  • HAL Allergy BV

  • Jubilant Life Sciences Ltd.

  • LETI Pharma SLU

  • Merck KGaA

  • Stallergenes Greer Ltd.


For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting